Chargement en cours...
Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial
SUMMARY: BACKGROUND: In the Denosumab and Teriparatide Administration (DATA) study, we showed that denosumab fully inhibits teriparatide-induced bone resorption while allowing for continued teriparatide-induced bone formation, resulting in larger increases in hip and spine bone mineral density (BMD)...
Enregistré dans:
| Publié dans: | Lancet Diabetes Endocrinol |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6980341/ https://ncbi.nlm.nih.gov/pubmed/31447409 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-8587(19)30255-4 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|